Abstracts tagged "diagnosis and prognostic factors"

Abstract Number: 406 • 2014 ACR/ARHP Annual Meeting
The Utility of HLA-DR Genotypification As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis
Fernando Dal Pra¹, Gustavo Citera², Margarita Landi³, Christian A. Waimann⁴, Luis Alejandro Cayetti², Sergio Paira⁵, Federico Ceccatto⁶, Teresita Alvarellos⁷, Luciana Mas⁷, Josefina Marcos⁸, Mercedes García⁸, A Salas⁸, Alejandro Martinez⁹, Rafael Chaparro¹⁰, Oscar Luis Rillo¹¹, Edson Veloso¹², Ricardo V. Juárez¹³, Maria Elena Crespo¹⁴, Antonio Catalán Pellet¹⁵, Anastasia Secco¹⁵, Lucila Marino¹⁶ and V Martire¹⁵, ¹Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Instituto Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital Olavarria, Olavarria, Argentina, ⁵Section of Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁶Rheumatology, Hospital Jose María Cullen, Santa Fé, Argentina, ⁷Laboratorio de Histocompatibilidad, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina, ⁸HIGA San Martín, La Plata, Argentina, ⁹Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹⁰Rheumatology, Hospital Gral. de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹¹Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ¹²Sanatorio y Universidad Adventista Del Plata, Entre Rios, Argentina, ¹³Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹⁴Hospital Señor Del Milagro, Salta, Argentina, ¹⁵Rheumatology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁶Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina
Background/Purpose: Only half of patients with undifferentiated arthritis (UA) will progress to rheumatoid arthritis (RA) after two years of follow-up. Particular human leukocyte antigens class…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].